* history of deep venous thrombosis or pulmonary embolism * hypercoagulable disorders (e.g. lupus anticoagulant, deficiency of protein c or s) * embolic stroke * liver disease * history of endometrial cancer * menopausal hormone therapy or oral, injectable or transdermal contraceptives * depression which is not optimally treated (assessed via medical record and patient will be asked if she/he feels that depression is optimally treated) * medications which prolong the qt interval (e.g. hydroxychloroquine or azithromycin) or those with long qt syndrome (heritable or acquired). examples of other medications which prolong the qt interval include: agents generally accepted to prolong qt interval include class 1a (e.g., quinidine, procainamide, disopyramide) and class iii (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron) (please refer to appendix for detailed list of medications) * inability to participate in follow up assessment * dementia/cognitive dysfunction * pregnancy (pregnancy testing will be performed to determine eligibility) * breastfeeding * participating in other covid-19 trials * immunodeficiency (including hiv, hepatitis c, bone marrow transplant history, on immunosuppressant medications) * current hospitalization * seizure disorder * history of rheumatoid arthritis * heart failure (nyha class iii or iv) * current diagnosis of renal insufficiency/failure * qtc \>470ms per 12-lead ecg * calcium \>10.2mg/dl * ast or alt \> 2x upper limit of normal (uln) * d-dimer \>= 1000 u/l * estimated glomerular filtration rate (egfr) \<60 ml/min/1.73 m2 * on other treatment(s) for covid-19 (e.g. hydroxychloroquine, remdesivir) * anticoagulant medications (e.g. coumadin, glycoprotein iia/iiib inhibitors) * clinical signs of severe or critical severity of covid-19 (e.g. shortness of breath at rest, respiratory rate ≥ 30 per minute, heart rate ≥ 125 per minute, spo2 ≤ 93% on room air) * use of supplemental oxygen * moderate to severe pulmonary disease up to pi discretion

* history of deep venous thrombosis or pulmonary embolism * hypercoagulable disorders (e.g. lupus anticoagulant, deficiency of protein c or s) * embolic stroke * liver disease * history of endometrial cancer * menopausal hormone therapy or oral, injectable or transdermal contraceptives * depression which is not optimally treated (assessed via medical record and patient will be asked if she/he feels that depression is optimally treated) * medications which prolong the qt interval (e.g. hydroxychloroquine or azithromycin) or those with long qt syndrome (heritable or acquired). examples of other medications which prolong the qt interval include: agents generally accepted to prolong qt interval include class 1a (e.g., quinidine, procainamide, disopyramide) and class iii (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron) (please refer to appendix for detailed list of medications) * inability to participate in follow up assessment * dementia/cognitive dysfunction * pregnancy (pregnancy testing will be performed to determine eligibility) * breastfeeding * participating in other covid-19 trials * immunodeficiency (including hiv, hepatitis c, bone marrow transplant history, on immunosuppressant medications) * current hospitalization * seizure disorder * history of rheumatoid arthritis * heart failure (nyha class iii or iv) * current diagnosis of renal insufficiency/failure * qtc \>470ms per 12-lead ecg * calcium \>10.2mg/dl * ast or alt \> 2x upper limit of normal (uln) * d-dimer \>= 1000 u/l * estimated glomerular filtration rate (egfr) \<60 ml/min/1.73 m2 * on other treatment(s) for covid-19 (e.g. hydroxychloroquine, remdesivir) * anticoagulant medications (e.g. coumadin, glycoprotein iia/iiib inhibitors) * clinical signs of severe or critical severity of covid-19 (e.g. shortness of breath at rest, respiratory rate ≥ 30 per minute, heart rate ≥ 125 per minute, spo2 ≤ 93% on room air) * use of supplemental oxygen * moderate to severe pulmonary disease up to pi discretion

- history of deep venous thrombosis or pulmonary embolism - hypercoagulable disorders (e.g. lupus anticoagulant, deficiency of protein c or s) - embolic stroke - liver disease - history of endometrial cancer - menopausal hormone therapy or oral, injectable or transdermal contraceptives - depression which is not optimally treated (assessed via medical record and patient will be asked if she/he feels that depression is optimally treated) - medications which prolong the qt interval (e.g. hydroxychloroquine or azithromycin) or those with long qt syndrome (heritable or acquired). examples of other medications which prolong the qt interval include: agents generally accepted to prolong qt interval include class 1a (e.g., quinidine, procainamide, disopyramide) and class iii (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron) (please refer to appendix for detailed list of medications) - inability to participate in follow up assessment - dementia/cognitive dysfunction - pregnancy (pregnancy testing will be performed to determine eligibility) - breastfeeding - participating in other covid-19 trials - immunodeficiency (including hiv, hepatitis c, bone marrow transplant history, on immunosuppressant medications) - current hospitalization - seizure disorder - history of rheumatoid arthritis - heart failure (nyha class iii or iv) - current diagnosis of renal insufficiency/failure - qtc >470ms per 12-lead ecg - calcium >10.2mg/dl - ast or alt > 2x upper limit of normal (uln) - d-dimer >= 1000 u/l - estimated glomerular filtration rate (egfr) <60 ml/min/1.73 m2 - on other treatment(s) for covid-19 (e.g. hydroxychloroquine, remdesivir) - anticoagulant medications (e.g. coumadin, glycoprotein iia/iiib inhibitors) - clinical signs of severe or critical severity of covid-19 (e.g. shortness of breath at rest, respiratory rate ≥ 30 per minute, heart rate ≥ 125 per minute, spo2 ≤ 93% on room air) - use of supplemental oxygen - moderate to severe pulmonary disease up to pi discretion

- history of deep venous thrombosis or pulmonary embolism - hypercoagulable disorders (e.g. lupus anticoagulant, deficiency of protein c or s) - embolic stroke - liver disease - history of endometrial cancer - menopausal hormone therapy or oral, injectable or transdermal contraceptives - depression which is not optimally treated (assessed via medical record and patient will be asked if she/he feels that depression is optimally treated) - medications which prolong the qt interval (e.g. hydroxychloroquine or azithromycin) or those with long qt syndrome (heritable or acquired). examples of other medications which prolong the qt interval include: agents generally accepted to prolong qt interval include class 1a (e.g., quinidine, procainamide, disopyramide) and class iii (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron) (please refer to appendix for detailed list of medications) - inability to participate in follow up assessment - dementia/cognitive dysfunction - pregnancy (pregnancy testing will be performed to determine eligibility) - breastfeeding - participating in other covid-19 trials - immunodeficiency (including hiv, hepatitis c, bone marrow transplant history, on immunosuppressant medications) - current hospitalization - seizure disorder - history of rheumatoid arthritis - heart failure (nyha class iii or iv) - current diagnosis of renal insufficiency/failure - qtc >470ms per 12-lead ecg - calcium >10.2mg/dl - ast or alt > 2x upper limit of normal (uln) - d-dimer >= 1000 u/l - estimated glomerular filtration rate (egfr) <60 ml/min/1.73 m2 - on other treatment(s) for covid-19 (e.g. hydroxychloroquine, remdesivir) - anticoagulant medications (e.g. coumadin, glycoprotein iia/iiib inhibitors) - clinical signs of severe or critical severity of covid-19 (e.g. shortness of breath at rest, respiratory rate ≥ 30 per minute, heart rate ≥ 125 per minute, spo2 ≤ 93% on room air) - use of supplemental oxygen - moderate to severe pulmonary disease up to pi discretion